![]() |
Name |
Octadecane, 9-ethyl-9-heptyl-
|
Molecular Formula | C27H56 | |
IUPAC Name* |
9-ethyl-9-heptyloctadecane
|
|
SMILES |
CCCCCCCCCC(CC)(CCCCCCC)CCCCCCCC
|
|
InChI |
InChI=1S/C27H56/c1-5-9-12-15-17-20-23-26-27(8-4,24-21-18-14-11-7-3)25-22-19-16-13-10-6-2/h5-26H2,1-4H3
|
|
InChIKey |
LRJHOBBNMAGOIG-UHFFFAOYSA-N
|
|
Synonyms |
Octadecane, 9-ethyl-9-heptyl-; 9-Ethyl-9-heptyloctadecane; 9-Ethyl-9-n-heptyloctadecane; 55282-27-4; NSC170888; 9-Ethyl-9-heptyloctadecane #; DTXSID70305493; NSC-170888
|
|
CAS | 55282-27-4 | |
PubChem CID | 298664 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 380.7 | ALogp: | 14.4 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 22 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 27 | QED Weighted: | 0.134 |
Caco-2 Permeability: | -5.12 | MDCK Permeability: | 0.00000388 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.364 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 98.35% |
Volume Distribution (VD): | 4.033 | Fu: | 1.27% |
CYP1A2-inhibitor: | 0.049 | CYP1A2-substrate: | 0.17 |
CYP2C19-inhibitor: | 0.12 | CYP2C19-substrate: | 0.435 |
CYP2C9-inhibitor: | 0.04 | CYP2C9-substrate: | 0.849 |
CYP2D6-inhibitor: | 0.426 | CYP2D6-substrate: | 0.043 |
CYP3A4-inhibitor: | 0.354 | CYP3A4-substrate: | 0.04 |
Clearance (CL): | 4.254 | Half-life (T1/2): | 0.012 |
hERG Blockers: | 0.401 | Human Hepatotoxicity (H-HT): | 0.052 |
Drug-inuced Liver Injury (DILI): | 0.041 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.076 |
Skin Sensitization: | 0.931 | Carcinogencity: | 0.022 |
Eye Corrosion: | 0.985 | Eye Irritation: | 0.914 |
Respiratory Toxicity: | 0.177 |